Severe acute respiratory syndrome coronavirus ORF7a inhibits bone marrow stromal antigen 2 virion tethering through a novel mechanism of glycosylation interference
JournalJournal of Virology
PublisherAmerican Society for Microbiology
MetadataShow full item record
AbstractSevere acute respiratory syndrome (SARS) emerged in November 2002 as a case of atypical pneumonia in China, and the causative agent of SARS was identified to be a novel coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV). Bone marrow stromal antigen 2 (BST-2; also known as CD317 or tetherin) was initially identified to be a pre-B-cell growth promoter, but it also inhibits the release of virions of the retrovirus human immunodeficiency virus type 1 (HIV-1) by tethering budding virions to the host cell membrane. Further work has shown that BST-2 restricts the release of many other viruses, including the human coronavirus 229E (hCoV-229E), and the genomes of many of these viruses encode BST-2 antagonists to overcome BST-2 restriction. Given the previous studies on BST-2, we aimed to determine if BST-2 has the ability to restrict SARS-CoV and if the SARS-CoV genome encodes any proteins that modulate BST-2's antiviral function. Through an in vitro screen, we identified four potential BST-2 modulators encoded by the SARS-CoV genome: the papain-like protease (PLPro), nonstructural protein 1 (nsp1), ORF6, and ORF7a. As the function of ORF7a in SARS-CoV replication was previously unknown, we focused our study on ORF7a. We found that BST-2 does restrict SARS-CoV, but the loss of ORF7a leads to a much greater restriction, confirming the role of ORF7a as an inhibitor of BST-2. We further characterized the mechanism of BST-2 inhibition by ORF7a and found that ORF7a localization changes when BST-2 is overexpressed and ORF7a binds directly to BST-2. Finally, we also show that SARSCoV ORF7a blocks the restriction activity of BST-2 by blocking the glycosylation of BST-2.
SponsorsNational Institute of Allergy and Infectious Diseases, NIAID: R01AI087452; National Institute of Allergy and Infectious Diseases, NIAID: RO1AI1095569
Bone Marrow Stromal Antigen 2
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84949652761&doi=10.1128%2fJVI.02274-15&partnerID=40&md5=8d733fa8a44c12c40ad0bf2aca7bcf1a; http://hdl.handle.net/10713/12408
- Severe acute respiratory syndrome coronavirus spike protein counteracts BST2-mediated restriction of virus-like particle release.
- Authors: Wang SM, Huang KJ, Wang CT
- Issue date: 2019 Oct
- p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1.
- Authors: Ma-Lauer Y, Carbajo-Lozoya J, Hein MY, Müller MA, Deng W, Lei J, Meyer B, Kusov Y, von Brunn B, Bairad DR, Hünten S, Drosten C, Hermeking H, Leonhardt H, Mann M, Hilgenfeld R, von Brunn A
- Issue date: 2016 Aug 30
- Middle East Respiratory Syndrome Coronavirus nsp1 Inhibits Host Gene Expression by Selectively Targeting mRNAs Transcribed in the Nucleus while Sparing mRNAs of Cytoplasmic Origin.
- Authors: Lokugamage KG, Narayanan K, Nakagawa K, Terasaki K, Ramirez SI, Tseng CT, Makino S
- Issue date: 2015 Nov
- Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins.
- Authors: Prentice E, McAuliffe J, Lu X, Subbarao K, Denison MR
- Issue date: 2004 Sep
- Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
- Authors: Chen L, Gui C, Luo X, Yang Q, Günther S, Scandella E, Drosten C, Bai D, He X, Ludewig B, Chen J, Luo H, Yang Y, Yang Y, Zou J, Thiel V, Chen K, Shen J, Shen X, Jiang H
- Issue date: 2005 Jun